Merck & Company
West Coast Innovation Hub
499 Illinois St. Suite 100
About Merck & Company
Meet representatives from Merck and connect with your Life Science peers at our 2018 Biotech Bay and Genetown Fall Talent Connect. Learn more about Merck here.
Merck and Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.
With approximately 60,000 employees, Merck conducts research at ten major research centers in the United States, Europe, and Japan, manufactures products in 30 facilities, and sells products in approximately 150 countries.
At Merck, our strategy for growth is based on breakthrough research - both internal and external through partnerships - and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2004 were $22.9 billion. Merck continues to invest heavily in research and development, with R&D spending in 2005 estimated to be approximately $4 billion.
Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, congestive heart failure, elevated cholesterol levels, osteoporosis, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, gastrointestinal ulcers, infectious diseases (antibiotic, anti-fungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B.
At Merck, we are strongly committed to partnership success. We have a long tradition of successful partnerships. Alliances with innovative partners are an integral part of our long-term business and research strategy. More than one-third of our sales are from alliance products and patents, including some of our biggest growth drivers.
Our vision is to create a "virtual lab" - the pursuit of the best scientific programs from both internal research and external collaborations. This approach will accelerate the successful development and commercialization of breakthrough discoveries that can bring meaningful improvements to patients' lives.
Our focus is seeking alliances for new NCE's and biological entities as product candidates for development. We are open to basic research collaborations and early research technologies as well.
Merck welcomes partnerships touching virtually all human health therapeutic areas that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories. Therapeutic areas of particular interest include cancer, central nervous system disorders, diabetes, and obesity. Also of interest include the following: anti-infectives, anti-virals, cardiovascular diseases, gastrointestinal diseases, immunology, new vaccine technology, ophthalmics, osteoporosis, pain, respiratory, vaccines, and platform research technology.
To contact Merck about a licensing opportunity, please contact Chief Licensing Officer, Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Fax: 908-735-1201. Please provide a brief, non-confidential overview of your discovery with sufficient data to allow a preliminary scientific review.
For further information, please visit our website at http://www.merck.com/licensing/
316 articles with Merck & Company
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)
With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for These Patients
Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
V920 is the Company’s Investigational Vaccine for Ebola Zaire
New Data from Investigational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
First presentation of LENVIMA and KEYTRUDA combination data in patients with metastatic non-small cell lung cancer, metastatic melanoma and metastatic urothelial carcinoma from Study 111/KEYNOTE-146
Early Phase 1 Data from Merck’s Oncology Pipeline for Investigational Anti-LAG-3 Therapy (MK-4280) and Anti-TIGIT Therapy (MK-7684) to Be Presented at SITC’s 33rd Annual Meeting
With New Data, Merck Now has Presented Early Clinical Data for Six Investigational Oncology Pipeline Candidates Spanning Several Pathways
Merck Halts Supply of Lifesaving Vaccine for African Kids to Seek Greater Profits in China, US, Says AHF
AHF condemns Merck for cutting off lifesaving vaccine for children dying from diarrhea in Africa while it also announces plans to expand distribution—and far more lucrative sales—in China
Increasing global reach of Embracing Carers™ to include Brazil and China
In what appears to be a trend, big pharma company AbbVie is leasing 479,000 square feet of space inBioMed Realty’s Gateway of Pacific project in South San Francisco.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Approval Based on Results of Phase 3 KEYNOTE-407 Trial, Which Demonstrated Superior Overall Survival with KEYTRUDA in Combination with Chemotherapy Compared to Chemotherapy Alone
NOXXON TO PRESENT TOP-LINE EFFICACY DATA FROM NOX-A12 / KEYTRUDA® COMBINATION TRIAL IN DECEMBER AS PLANNED AT ESMO IMMUNO-ONCOLOGY CONFERENCE
NOXXON Pharma N.V. announced today that it will report top-line efficacy data from the ongoing clinical trial (NCT03168139) testing NOX-A12 (olaptesed pegol) in combination with Merck & Co./MSD’s PD-1 inhibitor Keytruda® in metastatic, microsatellite stable pancreatic and colorectal cancer patients at the ESMO Immuno-Oncology Conference taking place in Geneva, Switzerland, December 13-16, 2018.
Increases Quarterly Dividend 15% to $0.55 per Outstanding Share
Third-Quarter 2018 Worldwide Sales Were $10.8 Billion
European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Melanoma
Opinion Granted Based on Significant Recurrence-Free Survival Benefit Demonstrated with KEYTRUDA in Pivotal Phase 3 EORTC1325/KEYNOTE-054 Trial
Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan
Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that the two companies have commenced joint medical and marketing activities for tyrosine kinase inhibitor LENVIMA (generic name: lenvatinib mesylate) in Japan.
Merck’s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer
Survival Benefit Observed with KEYTRUDA Monotherapy in Patients Whose Tumors Expressed PD-L1 with CPS≥20 and CPS≥1 and in Total Patient Population for KEYTRUDA in Combination with Chemotherapy
SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer
60 Percent of Patients Receiving LYNPARZA Remained Progression-Free at Three Years Compared to 27 Percent on Placebo Following Platinum-Based Chemotherapy
First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
New Clinical Findings Involving STING Agonist as Monotherapy and in Combination with an Anti-PD-1 Therapy
Multiple biotech companies are scheduled to release their quarterly reports next week. BioSpace takes a quick look at some these companies and the announcements they have made through 3Q2018.
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma
KEYTRUDA is First Anti-PD-1 Therapy in Combination to Improve Both OS and PFS in Advanced or Metastatic RCC, the Most Common Type of Kidney Cancer
Merck today announced the appointment of Jim Scholefield as chief information and digital officer, effective Oct. 29, 2018.
Fourth Orphan Drug Designation in the U.S. for AstraZeneca and Merck’s LYNPARZA